Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Paclitaxel (Taxol)]

R Hájek1

  • 1II. interní klinika FN, Brno - Bohunice.

Casopis Lekaru Ceskych
|June 12, 1996
PubMed
Summary
This summary is machine-generated.

Paclitaxel, a novel taxane chemotherapy, effectively treats advanced cancers like ovarian and breast cancer. While it can cause side effects, current protocols minimize risks, improving patient survival rates.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

Leukemia·2024
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same journal

The personality of professor Otakar Štark in the context of the development of medical genetics in Czechoslovakia in the years 1950-1990.

Casopis lekaru ceskych·2026
Same journal

Václav Náprstek, MD - a forgotten hero.

Casopis lekaru ceskych·2026
Same journal

Professor Otto Piffl, the First Full Professor of Otology and Rhinology at the German University in Prague, passed away 100 years ago.

Casopis lekaru ceskych·2026
Same journal

Ancient sanctuary of Eileithyia, goddess of childbirth, on the island of Paros (Greece).

Casopis lekaru ceskych·2026
Same journal

European Partnership for Personalised Medicine (EP PerMed).

Casopis lekaru ceskych·2026
Same journal

Periodontitis and type 2 diabetes.

Casopis lekaru ceskych·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Paclitaxel (TAXOL) is the first taxane antineoplastic agent in clinical use.
  • It functions by disrupting microtubule dynamics, crucial for cell division.

Purpose:

  • To review the pharmacokinetics, clinical efficacy, and adverse effects of paclitaxel.
  • To highlight its role in treating advanced ovarian, breast, lung, and other cancers.

Summary:

  • Paclitaxel exhibits nonlinear pharmacokinetics at higher doses or short infusions.
  • Key toxicities include neutropenia, neurotoxicity, and mucositis, manageable with premedication.
  • Significant efficacy is observed in ovarian, breast, and non-small cell lung cancers.

Impact:

  • Paclitaxel combined with cisplatin improves progression-free and overall survival in ovarian cancer.
  • It is approved in the Czech Republic for advanced ovarian and metastatic breast cancer post-standard therapy failure.